Advances in Gastrointestinal Cancers

Slides:



Advertisements
Similar presentations
Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck
Advertisements

Bladder Cancer: A New Era in Treatment
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
Treatment Algorithms in Melanoma: Past, Present, and Future
The Immune System. The Immune System Adaptive Immune Response.
Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advanced NSCLC Without Actionable Mutations
State of the Art in HCC: Immune Checkpoint Modulation
Case Studies.
Discussion Outline Cells of the Immune System.
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.
Progression After Cancer Immunotherapy in Advanced NSCLC
Updates in Lung Cancer: Insights From Vienna
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Activity Goals. Activity Goals Discussion Topics.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
The Evolving Role of Immunotherapy in NSCLC
Immunotherapy in Pancreatic Cancer: Thinking Outside the Box
Optimizing Management of Advanced Bladder Cancer
Basics of Immunotherapy Potential Therapeutic Targets.
Treating mRCC After Initial Antiangiogenic Therapy:
Advanced Lung Cancers: What's on the Horizon?
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Next-Gen Psoriasis Therapies:
Case Studies in Unresectable Hepatocellular Carcinoma
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Nat. Rev. Urol. doi: /nrurol
Immunotherapy for cSCC
Advancing Care in Genitourinary Cancer: Perspectives From Chicago
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.
Advancing Care Across the Spectrum of Pancreatic Cancer
Evolving Concepts in the Management of Head and Neck Cancers
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Immune Checkpoint Inhibitors in Lung Cancer
Locally Advanced Lung Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment
Challenges and Opportunities
Preparing for Checkpoint Inhibitors in Breast Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
From Adjuvant to Metastatic in Melanoma
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Case Studies in Locally Advanced Pancreatic Cancer
Peanut Allergy Immunotherapy
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
Going Beyond EXTREME in Head and Neck Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Moving Care Forward in Advanced Gastric Cancer
New Options for the Treatment of Hepatocellular Carcinoma
MSI.
Immune Checkpoint Inhibitors in Lung Cancer
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Recent Developments in the Treatment of Advanced and Metastatic RCC
Presentation transcript:

Advances in Gastrointestinal Cancers

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Immunotherapy in Gastrointestinal Malignancies

dMMR and PD-1 Blockade

dMMR and PD-1 Blockade (cont)

dMMR and PD-1 Blockade (cont)

Immunotherapy in Hepatocellular Carcinoma

Nivolumab Monotherapy in HCC CheckMate-040

CheckMate-040 Subset Analysis

Pembrolizumab Monotherapy in HCC KEYNOTE-224

Durvalumab Monotherapy in HCC

Dual Checkpoint Inhibitor Therapy in HCC

Combined VEGF Inhibition and PD-1 Inhibition in HCC

Ongoing Trials and Future Directions

Immunotherapy in Gastroesophageal Cancer

Pembrolizumab Monotherapy in Gastric/Gastroesophageal Cancer

Nivolumab Monotherapy in Gastric and GE Junction Cancer

Avelumab Monotherapy in Advanced Gastric or GE Junction Cancer

Pembrolizumab Monotherapy in Gastric and GE Junction Cancer

Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Nivolumab + Ipilimumab

Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Durvalumab + Tremelimumab

Combination VEGFR-2 and PD-1 Inhibition in the Second Line Management of Gastric or GE Junction Adenocarcinoma

Ongoing Trials and Future Directions

Immunotherapy in Pancreatic Adenocarcinoma

Immunotherapy in Pancreatic Cancer

Dual Checkpoint Inhibitors in Pancreatic Cancer

Chemotherapy in Combination With Checkpoint Inhibitors

Other Immunomodulating Agents IDO-1 Inhibitors

Other Immunomodulating Agents: CSF1R Blockade

Pancreatic Immunotherapy Ongoing trials

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)